Home > Insider Trading > Filing (0001567619-21-013730)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1623715	Imago Biosciences Inc.	IMGO	()	4

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1365617	J Patrick Heron	C/O Imago Biosciences, Inc. 329 Oyster Point Blvd, 3Rd Floor South San Francisco CA 94080	Yes	No	No	No
1553071	Frazier Healthcare Vii, L.p.	601 Union Street Suite 3200 Seattle WA 98101	No	No	Yes	No
1575192	Frazier Healthcare Vii-A, L.p.	601 Union Street Suite 3200 Seattle WA 98101	No	No	Yes	No
1654631	Fhm Vii, L.l.c.	601 Union Street, Suite 3200 Seattle WA 98101	No	No	Yes	No
1654632	Fhm Vii, L.p.	601 Union Street, Suite 3200 Seattle WA 98101	No	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2021-07-20	41,582	$16.00	41,582	No	4	P	Indirect	See Footnote
Common Stock	Acquisiton	2021-07-20	145,918	$16.00	145,918	No	4	P	Indirect	See Footnote
Common Stock	Acquisiton	2021-07-20	341,932	$0.00	383,514	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2021-07-20	211,069	$0.00	594,583	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2021-07-20	64,360	$0.00	658,943	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2021-07-20	1,199,890	$0.00	1,345,808	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2021-07-20	740,673	$0.00	2,086,481	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2021-07-20	225,850	$0.00	2,312,331	No	4	C	Indirect	See Footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	See Footnote
No	4	P	Indirect	See Footnote
No	4	C	Indirect	See Footnote
No	4	C	Indirect	See Footnote
No	4	C	Indirect	See Footnote
No	4	C	Indirect	See Footnote
No	4	C	Indirect	See Footnote
No	4	C	Indirect	See Footnote

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series A Preferred Stock	Disposition	2021-07-20	341,932	$0.00	341,932	$0.00
Common Stock	Series B Preferred Stock	Disposition	2021-07-20	211,069	$0.00	211,069	$0.00
Common Stock	Series C Preferred Stock	Disposition	2021-07-20	64,360	$0.00	64,360	$0.00
Common Stock	Series A Preferred Stock	Disposition	2021-07-20	1,199,890	$0.00	1,199,890	$0.00
Common Stock	Series B Preferred Stock	Disposition	2021-07-20	740,673	$0.00	740,673	$0.00
Common Stock	Series C Preferred Stock	Disposition	2021-07-20	225,850	$0.00	225,850	$0.00

Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect

Footnotes

These shares are held directly by Frazier Healthcare VII-A, L.P. ("FH VIIA"). The general partner of FH VIIA is FHM VII, L.P. and the general partner of FHM VII, L.P. is FHM VII, L.L.C., and each may be deemed to have sole voting, investment and dispositive power with respect to the shares held by FH VIIA. The Reporting Person is one of six members of FHM VII, L.L.C. The Reporting Person, FHM VII, L.P. and FHM VII, L.L.C. each disclaim Section 16 beneficial ownership of the securities held by FH VIIA, except to the extent of his or its pecuniary interest therein, if any.
These shares are held directly by Frazier Healthcare VII, L.P. ("FH VII"). The general partner of FH VII is FHM VII, L.P. and the general partner of FHM VII, L.P. is FHM VII, L.L.C., and each may be deemed to have sole voting, investment and dispositive power with respect to the shares held by FH VII. The Reporting Person is one of six members of FHM VII, L.L.C. The Reporting Person, FHM VII, L.P. and FHM VII, L.L.C. each disclaim Section 16 beneficial ownership of the securities held by FH VII, except to the extent of his or its pecuniary interest therein, if any.
Each share of the Issuer's Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering on July 20, 2021 and had no expiration date.